Project Grant R21CA301173
Award Date 3/18/26
Completion Date 2/29/28
Dollars Obligated $411K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $2.84 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Maryland, Baltimore, with a performance period from August 18, 2025, through July 30, 2029. This research initiative aims to develop and optimize novel dual-activation compounds that enhance the therapeutic efficacy of cyclophosphamide (CPA) and doxorubicin (DOX)-based chemotherapy regimens used to treat triple-negative...
- Federal Grant Award Summary The National Cancer Institute awarded University of Maryland, Baltimore a $422,799 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective September 5, 2025, through August 31, 2027. The award supports research on therapeutic targeting and biophysical characterization of Chimeric Antigen Receptor (CAR)-mediated trogocytosis, a resistance mechanism that undermines the efficacy of CAR T cell therapy for blood cancers. The research will...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $510,431 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2025 through June 30, 2030. This award supports fundamental research investigating the mechanisms of metastatic recurrence and therapeutic resistance in melanoma, with particular emphasis on understanding how aging influences tumor dormancy and the microenvironment. The research examines Wnt signaling...
- Federal Project Grant Award Summary New York University received a $427,085 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 7, 2025, with completion targeted for July 31, 2027. The award supports investigative research examining the interplay between social determinants of health (SDOH) and the mammalian target of rapamycin (mTOR) pathway in post-treatment cancer-related fatigue (CRF) among prostate...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $375,025 Research Specialist (R50) Award to the University of Maryland, Baltimore under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through June 30, 2029. This award provides protected time and institutional resources to support Dr. Mark Mishra's leadership role in expanding NCI-funded clinical trial activities across the University of Maryland Greenebaum Comprehensive Cancer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded a $513,127 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Biology Research program (CFDA 93.396) effective September 9, 2025, with completion targeted for August 31, 2030. This award funds a multidisciplinary research initiative investigating the relationship between cancer pain-associated sensory neuron activity and malignant peripheral nerve sheath tumor (MPNST) progression. The research team...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...